Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Scaife

Vascular Surgery Henrico, VA Medical Doctor

NPI 1710322193 CMS profile 6005606

7900 Shrader Rd, Henrico, VA 23294

Open in the dashboard

General payments

$44,452

319 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Scaife of Henrico, VA is reported in the CMS Open Payments database as having received $44,452 across 319 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,735 38
2024 General $6,066 42
2023 General $11,381 49
2022 General $8,617 42
2021 General $3,675 74
2020 General $11,196 49
2019 General $1,782 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Scaife
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Mark Scaife were reported at $1,735. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Mark Scaife Vascular Surgery median Middle half National median
2019 $1,782 $796 $226–$2,363 $163
2020 $11,196 $348 $118–$1,110 $114
2021 $3,675 $471 $158–$1,421 $132
2022 $8,617 $725 $222–$2,183 $149
2023 $11,381 $836 $257–$2,440 $160
2024 $6,066 $909 $252–$2,619 $164
2025 $1,735 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AngioDynamics, Inc. $13,902 10 payments
  2. Medtronic Vascular, Inc. $10,283 26 payments
  3. Medtronic, Inc. $6,216 82 payments
  4. W. L. Gore & Associates, Inc. $4,441 41 payments
  5. Penumbra, Inc. $2,511 35 payments
  6. Boston Scientific Corporation $2,248 35 payments
  7. Philips Electronics North America Corporation $1,089 36 payments
  8. Shockwave Medical, Inc $919 16 payments
  9. Silk Road Medical, Inc. $787 6 payments
  10. Endologix, Inc. $239 2 payments
  11. Other $1,816 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,726 289 payments
  2. Long term medical supply or device loan $13,833 6 payments
  3. Grant $9,172 3 payments
  4. Travel and Lodging $5,480 19 payments
  5. Education $240 2 payments
Products named General payments · program years 2019–2025
  1. Auryon Laser System 100-120 Vac $13,833 6 payments
  2. Endurant Aortic Stent Grafts $9,714 22 payments
  3. ENDURANT IIS $3,498 39 payments
  4. GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis $1,929 9 payments
  5. Indigo System $1,581 15 payments
  6. GORE TAG Thoracic Endoprosthesis $1,470 12 payments
  7. General - Therapies $1,255 6 payments
  8. Endurant Aortic Stent Grafts $1,081 22 payments
  9. ELLIPSYS VASCULAR ACCESS SYSTEM $894 5 payments
  10. ENROUTE 0.014 Guidewire $434 3 payments
  11. Other $10,308 193 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

208

Median for Vascular Surgery: 122

Drug cost

$35,539

Median for Vascular Surgery: $14,135

Branded share of claims

56.2%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 38 $19,602
Xarelto Rivaroxaban Brand 22 $15,288
Clopidogrel Clopidogrel Bisulfate Brand 57 $435
Tramadol Hcl Generic 91 $215

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 141 billing codes

Paid by Medicare

$548,203

Of which drugs: $61

Medicare patients

1,556

Average age 77

Services billed

3,393

835 women, 721 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 44%
Ischemic heart disease 44%
Chronic kidney disease 44%
Heart failure 38%
Atrial fibrillation 34%
Depression 31%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, fentanyl citrate, 0.1 mg J3010 Office 35 60 $45
Injection, midazolam hydrochloride, per 1 mg J2250 Office 40 116 $12

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

319 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record